ASAleksandra Senat

Aleksandra Senat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aleksandra Senat has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Endometriosis: Pathogenesis, diagnosis, treatment and the role of gut microbiota

    by Hanna Senat, Patrycja Grabowska, Aleksandra Senat, Patrycja Bolla, Aleksandra Madej, Zuzanna Marczyńska, Karolina Libracka

    Endometriosis is a common disease. It affects 5-10% of women of reproductive age worldwide. However, despite the prevalence, diagnosis is typically delayed by years, misdiagnosis is common, and effective treatment takes years to achieve. Determining the mechanisms involved in its pathogenesis is vital, not only to pave the way for early identification, but also for disease management and development of less invasive but successful treatment strategies. Three main typed of endometriosis have been described in literature: peritoneal, ovarian and deep infiltrative. This is mainly due to the most common locations of ectopis endometrium. .Determining the precise pathogenesis of endometriosis has proved challenging and controversial for gynecologists, endocrinologists and researchers, but recent studies have focused on finding answers. This disease is often asymptomatic and diagnosed incidentally during various surgical interventions or follow-up gynecological examinations. Epidemiological research reports that women with this disease are more vulnerable to ovarian and breast cancer, asthma, skin cancer suhc as melanoma, cardiovascular disease and rheumatoid arthritis. The connection of the gut microbiota and endometriosis is nowadays higly suspected to exist. Scientists are focused on the influence of the microbiome on estrogens, estrogens-dependent disorders, immune system and inflammation. It is strongly velieved that correction of the gut microbiota with antibiotica, probiotics, or fecal bacterial transplantation sie a hopeful method for improving the clinical management of endometriosis.

  • Open Access

    Gestational trophoblastic disease a contemporary review of diagnostic and pathology. Current challenge and future directions for gynecologists and obstetricians

    by Hanna Senat, Patrycja Grabowska, Aleksandra Senat, Patrycja Bolla, Aleksandra Madej, Zuzanna Marczyńska

    Gestational trophoblastic disease (GTD) is a heterogenous group of disorders assosiated with abnromal proliferation of trophoblast and their course is characterized by varying degrees of malignancy. WHO classified GTD into three categories: tumor-like lesions, molar pregnancies and gestational trophoblastic neoplasms.HM is characterized by abnormal proliferation of both syncytiotrophoblast and cytotrophoblast, edema of placental villi, with or without the presence of a fetus. Complete and partial moles have been classified as two separate disease entities, and their division depends on the genetic material they contain. The complete mole has a complete set of chromosomes coming only from paternal genome, while the partial mole is triploid and the genetic material transferred comes from the father and the mother. Post-molar gestational trophoblast neoplasia (GTN) is a clinical diagnosis based on the observation of a persistent increase or persistently high hCG concentration after evacuation of the mole, requiring evaluation and treatment. Invasive hydatidiform mole, together with choriocarcinoma and placental tumor, belong to gestational trophoblast neoplasia. Currently, research has shown that short tandem repeat (STR) genotyping is the gold standard for making the correct diagnosis and this test should be performed if possible. GTD diseases originate from both syncytiotrophoblast and cytotrophoblast tissues and as a result of which they produce an extremely sensitive marker -human chorionic gonadotropin. The facts stated above and significant sensitivity to chemotherapy mean that the average cure rate for this disease currently exceeds 90%. Although the main treatment of gestational trophoblast neoplasia involves the use of cytostatics in cases with worse prognosis, i.e. those with a higher risk, surgery turns out to be an invaluable treatment method.

  • Open Access

    The Prevalence of extraintestinal manifestations in Inflammatory Bowel Disease

    by Aleksandra Madej, Hanna Senat, Patrycja Grabowska, Patrycja Bolla, Aleksandra Senat, Zuzanna Marczyńska

    INTRODUCTION: The term inflammatory bowel disease (IBD) refers to a chronic inflammatory disease of the gastrointestinal tract of unclear pathogenesis. IBD consists of ulcerative colitis (UC) and Crohn's disease (CD). The two most common manifestations of the disorder, both have a chronic course with episodes of acute activity. Their underlying pathogenesis and symptoms, however, are quite distinct. IBD has a multiple factor etiology involving genetics, immunological dysregulation and dysbiosis of the intestinal microbiome. The resulting chronic inflammation of the entire body is the cause of the symptoms and signs of the condition. Extraintestinal manifestations (EIM) occur in 5% to 50% of IBD patients over the course of their lifetime. PURPOSE: The aim of the study is to present the current state of knowledge about the prevalence of extraintestinal manifestations in Inflammatory Bowel Disease. MATERIALS AND METHOD: The available literature in PubMed was reviewed to write the article, using the keywords ,,inflammatory bowel disease”, ,,Crohn’s disease”, ,, ulcerative colitis”, ,,extraintestinal manifestations IBD”. CONCLUSION: Extraintestinal manifestations are evidence that IBD is not only confined to the intestine, these may involve many different organs other than the gut and may be more devastating than the IBD. Screening for EIM in these patients and prompt adequate treatment are essential. To adequately manage EIM and improve the quality of life of our patients, appropriate treatment regimens and therapies are required in a multidisciplinary team approach. Due to the lack of available dedicated diagnostic biomarkers for EIM, consideration of concomitant extraintestinal conditions in patients with inflammatory bowel disease might help in the selection and management of them. Clinicians caring for patients with IBD must be aware of these various systemic manifestations, as failure to diagnose and treat them early can result in significant morbidity.


  • Open Access

    Does prenatal exposure to antidepressants cause autism? - literature review

    by Zuzanna Marczyńska, Patrycja Grabowska, Natalia Olesińska, Patrycja Bolla, Hanna Senat, Aleksandra Senat, Aleksandra Madej

    Autism spectrum disorder is an increasingly diagnosed disorder among children, yet its pathogenesis is still unknown. Possible causes are sought in genetic mutations, cellular processes occurring in the nervous system during development and external factors affecting the fetus during the prenatal period. In recent years, there have been an increasing number of reports linking the occurrence of the spectrum to antidepressant medications, especially from the SSRI group, taken by pregnant women for depressive disorders, which occur in up to a dozen percent of women in this group. The involvement of serotonin in the development of the nervous system during the fetal period is taken as the reason for this phenomenon. To date, no clear consensus has been reached on this issue, and many distractors in the research are highlighted, such as the effect of maternal depression on fetal development, among others. There is no doubt that further research is needed to better assess the risk of ASD associated with SSRI use and dosage during pregnancy

  • Open Access

    The influence of the ketogenic diet on the therapy of type 2 diabetes. A literature review

    by Aleksandra Madej, Hanna Senat, Patrycja Grabowska, Patrycja Bolla, Aleksandra Senat, Zuzanna Marczyńska, Mateusz Dorochowicz

    INTRODUCTION: Diabetes mellitus type 2 (DM2) is a widespread and chronic disorder with high mortality and associated morbidity rates worldwide. DM2 individuals are more susceptible to developing heart disease, cardiovascular disease, diabetic neuropathy, and several other related complications, which are major causes of diabetes related death. New therapies and possibilities for the treatment of the diabetes are constantly being searched for, among which the ketogenic diet is increasingly becoming popular. There are studies being conducted all worldwide on the effects of this diet on the treatment of diabetes. PURPOSE: The aim of the study is to present the current state of knowledge about the influence of the ketogenic diet on the therapy of type 2 diabetes. MATERIALS AND METHOD: The available literature in PubMed was reviewed to write the article, using the keywords ,,ketogenic diet”, ,,diabetes mellitus”, ,,ketogenic diet diabetes”, ,,diabetes nutrition”. CONCLUSION: A ketogenic diet has notable advantages on body weight and glycemic control, as well as on the enhancement of lipid profiles in overweight DM2 patients. This diet can decrease body weight, waist circumference, HbA1c, and triglycerides, and increase HDL levels. In addition, the ketogenic diet may have further benefits in improving body composition to attenuate the onset and progress of DM2 bz reducing body weight, lowering glycemic levels, and enhancing lipid profiles. More studies are needed in the future to support and even confirm the links between the ketogenic diet and patienst suffering from DM2.


  • Open Access

    Sarcoidosis. A review of diagnosis, clinical features and treatment

    by Aleksandra Madej, Hanna Senat, Patrycja Grabowska, Patrycja Bolla, Aleksandra Senat, Zuzanna Marczyńska

    Introduction: Sarcoidosis is a progressive chronic multisystemic inflammatory disease of unclear pathogenesis, which presents with noncaseating granulomas and is complicated to diagnose due to the variable clinical presentation of patients. Sarcoidosis may attack any organ, but especially the pulmonary, cutaneous, lymphatic, ocular, hepatic and splenic systems. The most frequent presentations are prolonged cough, rash, visual problems, peripheral lymphadenopathy, tiredness, and occasional abnormality of the chest X-ray. The diagnostic evaluation of sarcoidosis is difficult and often involves a combined effort of clinical data and appropriate imaging modalities. Purpose: The purpose of this article is to review the available literature on the epidemiology, clinical manifestations and management of patients with sarcoidosis Materials and method: The available literature in PubMed was reviewed to write the article, using the keywords ,,sarcoidosis”, ,,cardiac sarcoidosis”, ,,pulmonary sarcoidosis” and ,,cutaneous sarcoidosis”. Conclusion: Sarcoidosis is associated with a significant increase in patient mortality, as well as decreased quality of life and physical disability. Efforts to accurately predict disease progression allow for more comprehensive and personalized patient care. As a life threatening disease, sarcoidosis needs to be diagnosed early and treated appropriately.


  • Open Access

    Diagnostic problems of rare diseases - amyloidosis. A case report

    by Hanna Senat, Patrycja Grabowska, Aleksandra Senat, Patrycja Bolla, Aleksandra Madej, Iwona Matus, Natalia Janicka, Zuzanna Marczynska

    The presented case study focuses on the complexities and challenges in diagnosingone of the forms of amyloidosis, where abnormal protein (amyloid) deposits in variousorgans and tissues lead to affection of many organs, especially the heart, kidneys, liver,spleen, and occasionally the central nervous system. Its aetiology remains largely unknown,making diagnosis and treatment particularly challenging.This report details the case of an 88-year-old patient, disabled for months (with amodified Rankin Scale score of 4), who presented to the Neurology Department with suddenright limb paresis and speech disorders. Initial assessments indicated suggested ischemicstroke, and patients received thrombolysis. Further laboratory tests and imaging, includingserum protein electrophoresis and computer tomograph (CT) scans, suggested transthyretinamyloidosis (ATTR), which was later confirmed through genetic testing.This case underscores the rapid, multi-organ progression of amyloidosis and itsdevastating impact, highlighting the necessity for early diagnosis and a multidisciplinarytreatment approach.Despite ongoing research, the pathogenesis of amyloidosis remains elusive, andcurrent treatment options are primarily symptomatic. This study aims to shed light on thediagnostic difficulties and the urgent need for timely intervention in amyloidosis cases.

  • Open Access

    The role of the gut microbiota in the pathogenesis and therapy of type 2 diabetes mellitus

    by Aleksandra Madej, Hanna Senat, Patrycja Grabowska, Patrycja Bolla, Aleksandra Senat, Zuzanna Marczyńska, Anna Niemczyk, Mateusz Dorochowicz

    INTRODUCTION: Diabetes mellitus type II (DM2) is one of the most frequently diagnosed diseases worldwide with a constantly increasing prevalence. It represents an important clinical challenge. The studies are concentrating on improving our knowledge of both pathogenesis and therapeutic opportunities. The influence of intestinal flora on many health conditions is being investigated. It was found that the gut microbiota of the healthy and diabetic individuals are different. This provides a highly important focus for the consideration of whether and how, based on the content of the intestinal flora, the development and treatment of this disease and its complications can be affected. PURPOSE: The aim of the study is to present the current state of knowledge about the The role of the gut microbiota in the pathogenesis and therapy of type 2 diabetes. MATERIALS AND METHOD: The available literature in PubMed was reviewed to write the article, using the keywords ,,gut microbiota diabetes”, ,,diabetes mellitus”, ,,intestinal microbiome diabetes”, ,,dysbiosis diabetes” and ,,gut microbiota diabetes”. CONCLUSION: The intestinal microbiome is a diverse community of microorganisms that inhabit the gut and has been shown to be essential for the health of the body. Modifications in the diversity and frequency of microorganisms residing in the gut, and the accumulation of metabolites they generate, have been correlated with DM2. The study of intestinal microflora could lead to the discovery of new methods of diagnosis and therapies of DM2 and its complications, such as diabetic kidney disease, neuropathy, retinopathy and cardiovascular disease. In conclusion, further studies are needed to understand the role of the gut microbiome in the pathogenesis and therapy of DM2.